Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Brian J. Sworder(Stanford University), David M. Kurtz(Stanford University), Stefan Alig(Stanford University), Matthew J. Frank(Stanford Blood Center), Navika Shukla(Stanford University), Andrea Garofalo(Stanford University), Charles Macaulay(Stanford University), Mohammad Shahrokh Esfahani(Stanford University), Mari Olsen(Stanford University), James N. Hamilton(Stanford University), Hitomi Hosoya(Stanford University), Mark Hamilton(Stanford Blood Center), Jay Y. Spiegel(Stanford Blood Center), John H. Baird(Stanford Blood Center), Takeshi Sugio(Stanford University), Mia Carleton(Stanford University), Alexander Craig(Stanford University), Sheren Younes(Stanford University), Bita Sahaf(Stanford Blood Center), Natasha Sheybani(Stanford University), Joseph G. Schroers‐Martin(Stanford Medicine), Chih Long Liu(Stanford University), Jean Oak(Stanford University), Michael C. Jin(Stanford University), Sara Beygi(Stanford University), Andreas Hüttmann(Essen University Hospital), Christine Hanoun(Essen University Hospital), Ulrich Dührsen(Essen University Hospital), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Michael S. Khodadoust(Stanford University), Yasodha Natkunam(Stanford University), Robbie G. Majzner(Stanford Medicine), Crystal L. Mackall(Parker Institute for Cancer Immunotherapy), Maximilian Diehn(California Institute for Regenerative Medicine), David B. Miklos(Stanford Blood Center), Ash A. Alizadeh(California Institute for Regenerative Medicine)
Cited by 132Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis